"We also recruited a CFO, made several other key hires, including a Vice President for Pulp & Paper Enzymes, and added experienced members to our Board of Directors," Mr. Emalfarb continued. "While we continue to experience the residual effects of the lack of funding over the prior two years, I am confident that with a strong balance sheet and our experienced team in place to advance our plans, Dyadic is well-positioned to pursue its many promising areas of growth."
Dyadic International Inc, is engaged in the development, manufacture and sale of biological products (proteins, enzymes, peptides and other bio-molecules), as well as the licensing of its enabling proprietary technology to business collaborators for the discovery, development and manufacture of biological products from genes.
Dyadic markets its products and services for applications in the textile, chemical, agricultural, pulp & paper, pharmaceutical, biotechnology and other industries, using its proprietary C1 Host Technology and C1 Expression and Screening Systems for the discovery, development and production of biological products.
Dyadic International Inc.
marketing@alchempro.com
